AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 312 min read$AVR

L1 Capital Pty Ltd sold $5.8M of AVR (indirect holdings)

L1 Capital Pty Ltd sold 714,138 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $8.17 ($8.04–$8.20, $5.83M total) across 2 trades over 2026-07-29 to 2026-07-30.

Original reporting
SEC EDGAR · L1 Capital Pty Ltd
Published Jul 31, 2026, 10:25 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 10:27 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

A 10% owner (L1 Capital Pty Ltd) sold $5.83M of AVR shares across two open-market trades at roughly $8.04 to $8.20, with holdings after sale reported at 6,633,314 shares.

02

Market read

Traders may monitor AVR for sentiment effects from a sizable holder sale, but the filing does not introduce new operational or financial catalysts.

03

What to watch

Because the holdings are indirect and the filing lacks stated rationale, traders may over-interpret the signal versus the broader context of the holder’s portfolio and tax/liquidity needs.

Relevance 6/10Novelty 4/10Timing: filed 2026-07-31, covering sales dated 2026-07-29 to 2026-07-30

Background

The article is an SEC Form 4 insider transaction disclosure for Anteris Technologies Global Corp. (AVR).

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

L1 Capital Pty Ltd, a 10% owner, sold 714,138 AVR shares in open-market trades at $8.0400 to $8.2000, totaling $5.83M, via indirect holdings.

Expected impact

Near-term impact is likely limited, with any effect more sentiment-driven than fundamental.

Evidence & confidence

Form 4 shows the transaction size and price range, but provides no new company-specific operating or financial information; also notes no 10b5-1 plan.

Market effects

Sector

No direct sector read-through; this is company-specific ownership activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The absence of a 10b5-1 plan does not necessarily imply negative information; sales can be liquidity or diversification-driven.

Key entities

  • issuer
    Anteris Technologies Global Corp.

    Subject of the Form 4 insider transaction disclosure, ticker AVR.

  • 10% owner
    L1 Capital Pty Ltd

    Reporter of the indirect open-market sale of AVR shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AVR insider trading history →

Related articles

AUG 12
$AVRMed

Anteris Advances DurAVR Toward Commercialization; PARADIGM Trial Expands U.S. Recruitment

Anteris Technologies Global Corp. (AVR) reported Q2 2026 results and said it secured U.S. Medicare reimbursement eligibility for PARADIGM Trial procedures. The company began U.S. recruitment, with first patients treated in May 2026, and said the trial is recruiting in the U.S., Denmark and the Netherlands. Net operating cash outflow was $20.8M; R&D expense was $23.4M.

rttnews.com5 min
AUG 12
$AVRMed

Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.

proactiveinvestors.com.au4 min
AUG 11
$AVRMedAI 8/10

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.

leaderpost.com6 min
AUG 11
$AVRLow

Anteris Technologies Global Corp. (AVR): Results of Operations and Financial Condition

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe

SEC EDGAR 8-K4 min
JUN 4
$AVRMed

Anteris Technologies Global (NASDAQ:AVR) Shares Up 12.6% – Should You Buy?

Anteris Technologies Global (NASDAQ:AVR) shares rose 12.6% to $10.0750 on Thursday, after closing at $8.95; the stock traded between $9.71 and $10.0750. Volume was 176,960 shares, down 84% vs. average. Analysts cited mixed views: Barclays raised its target to $18 (overweight), while Wall Street Zen moved to hold; consensus target is $16. In its May 12 earnings, the company reported -$0.28 EPS vs -$0.27 expected on $0.49M revenue vs $0.77M.

tickerreport.com5 min